Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19NO.ClH |
| Molecular Weight | 301.811 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNCC\C=C1\C2=CC=CC=C2OCC3=C1C=CC=C3
InChI
InChIKey=GNPPEZGJRSOKRE-QFHYWFJHSA-N
InChI=1S/C18H19NO.ClH/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18;/h2-5,7-11,19H,6,12-13H2,1H3;1H/b16-10+;
Approval Year
Sample Use Guides
In 'metabolic consumption' experiments with liver microsomes (having measurable CYP2D6 activity) and initial substrate concentration of 1 microM, the consumption of E-doxepin was greater than that of Z-doxepin. With N-desmethyldoxepin, quinidine inhibited the consumption of E-N-desmethyl-doxepin whereas Z-N-desmethyldoxepin appeared to be a terminal oxidative metabolite. CYP2D6 is a major oxidative enzyme in doxepin metabolism; predominantly catalysing hydroxylation with an exclusive preference for the E-isomers. The relatively more rapid metabolism of E-isomeric forms, and the limited metabolic pathways for the Z-isomers explained the apparent enrichment of Z-N-desmethyldoxepin.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4VQL417S2G
Created by
admin on Sat Dec 16 05:27:24 GMT 2023 , Edited by admin on Sat Dec 16 05:27:24 GMT 2023
|
PRIMARY | |||
|
4504-96-5
Created by
admin on Sat Dec 16 05:27:24 GMT 2023 , Edited by admin on Sat Dec 16 05:27:24 GMT 2023
|
PRIMARY | |||
|
6506545
Created by
admin on Sat Dec 16 05:27:24 GMT 2023 , Edited by admin on Sat Dec 16 05:27:24 GMT 2023
|
PRIMARY | |||
|
DTXSID30196369
Created by
admin on Sat Dec 16 05:27:24 GMT 2023 , Edited by admin on Sat Dec 16 05:27:24 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
